Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Prologis Inc (PLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Prologis Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Prologis Inc trades at $140.68 (market cap $133.89B). The key difference: Prologis Inc is far larger — about 29.8× ACADIA Pharmaceuticals Inc.'s market cap, and Prologis Inc pays a 2.98% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PLD | |
|---|---|---|
Market Cap | $4.49B | $133.89B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $148.74 |
52-Week Low | $20.06 | $104.08 |
Enterprise Value | $3.69B | $167.77B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Prologis (PLD) trades at $143.61, up 2.98% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 41.54% net income margin and a $1.07 dividend payment scheduled for June 30, 2026. Recent news highlights a rejected $16.6 billion takeover bid for Segro, indicating aggressive growth ambitions. Cash flow trends remain volatile, with 2025 net cash flow negative at -$172.94 million, though operating cash flow stays robust at $5.01 billion.
Outlook is positive with a consensus price target of $155.20, offering 8% upside. Risks include rising debt-to-asset ratio (37.2% in 2025) and macroeconomic sensitivity. The bullish analyst consensus (57% buy ratings) supports growth from data center expansion and rent spreads, but investors should monitor leverage and acquisition integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
